(AOF) – Biosynex has announced that it has acquired 100% of the securities of the start-up Doc2U, a Toulouse company created in September 2020. The solution developed by the Toulouse company includes in a single device the main tools necessary for measuring certain vital parameters. and physiological conditions of the patient (body temperature, blood pressure, heart rate, oxygen saturation). Attached to the wrist, the autonomous and connected device can also transmit the image and sound of an otoscope and a stethoscope.
Backed by technical and regulatory know-how as well as a network of French industrial partners, Doc2U designs its products in-house and has them manufactured in France.
Biosynex will deploy the One product in France and internationally and integrate it into its range of complementary self-measurement products.
Through this new acquisition, Biosynex continues to strengthen its presence and expertise in the fields of self-measurement and medical devices.
AOF – LEARN MORE
An inevitable race for new blockbusters
The patent for Merck’s star product, the cancer drug Keytruda, which accounts for more than 35% of its sales, expires in 2028. Despite the loss, since 2019, of the patents for its three star products (Avastin, Herceptine, Rituxan) Roche was able to renew its portfolio by bringing new molecules to market. However, the discovery and launch of new drugs are increasingly expensive. AstraZeneca spends about $6 billion a year on R&D in a pharmaceutical industry where the life of a patent only lasts ten to fifteen years. This leads laboratories to withdraw from certain activities. Thus J&J, Pfizer, GSK and, no doubt, Novartis soon prefer to refocus on specialty drugs and abandon any ancillary activity.